CRISPR Therapeutics (CRSP)

• Market cap: $3.17B
• 1 day: -2.76%
• 5 days: -11.93%
• 1 month: -15.78%
• 3 months: -4.29%
• 6 months: -21.26%
• Year to date: -10.72%
• 1 year: -45.73%
• 5 years: -16.48%
• 10 years: 162.53%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

5.36% more ownership

Funds ownership: 70.23% [Q3] → 75.59% (+5.36%) [Q4]

5% less repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 118

6% less first-time investments, than exits

New positions opened: 65 | Existing positions closed: 69

3% less funds holding

Funds holding: 409 [Q3] → 395 (-14) [Q4]

10% less capital invested

Capital invested by funds: $2.81B [Q3] → $2.54B (-$268M) [Q4]

11% less call options, than puts

Call options by funds: $81.6M | Put options by funds: $91.6M

20% less funds holding in top 10

Funds holding in top 10: 5 [Q3] → 4 (-1) [Q4]

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $32 13% downside
• Avg. target: $73 97% upside
• High target: $120 224% upside

13 analyst ratings

• positive: 8 62%
• neutral: 4 31%
• negative: 1 8%

Citigroup Yigal Nochomovitz 19% 1-year accuracy 8 / 43 met price target	122% upside $82	Buy Maintained	18 Feb 2025
Morgan Stanley Terence Flynn 37% 1-year accuracy 7 / 19 met price target	13% downside $32	Underweight Maintained	14 Feb 2025
Evercore ISI Group Liisa Bayko 55% 1-year accuracy 6 / 11 met price target	168% upside $99	Outperform Upgraded	14 Feb 2025
Goldman Sachs Salveen Richter 29% 1-year accuracy 5 / 17 met price target	54% upside $57	Neutral Maintained	13 Feb 2025
JMP Securities Silvan Tuerkcan 23% 1-year accuracy 12 / 53 met price target	133% upside $86	Market Outperform Reiterated	13 Feb 2025